Search

Your search keyword '"Masri, Ahmad"' showing total 803 results
Start Over Author "Masri, Ahmad"
803 results on '"Masri, Ahmad"'

1. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform

Author

Conceição, Isabel, Berk, John L., Weiler, Markus, Kowacs, Pedro A., Dasgupta, Noel R., Khella, Sami, Chao, Chi-Chao, Attarian, Shahram, Kwoh, T. Jesse, Jung, Shiangtung W., Chen, Jersey, Viney, Nicholas J., Yu, Rosie Z., Gertz, Morie, Masri, Ahmad, Cruz, Márcia Waddington, and Coelho, Teresa

Published
2024
Full Text
View/download PDF

3. Patient-Level Artificial Intelligence–Enhanced Electrocardiography in Hypertrophic Cardiomyopathy Longitudinal Treatment and Clinical Biomarker Correlations

Author

Siontis, Konstantinos C, Abreau, Sean, Attia, Zachi I, Barrios, Joshua P, Dewland, Thomas A, Agarwal, Priyanka, Balasubramanyam, Aarthi, Li, Yunfan, Lester, Steven J, Masri, Ahmad, Wang, Andrew, Sehnert, Amy J, Edelberg, Jay M, Abraham, Theodore P, Friedman, Paul A, Olgin, Jeffrey E, Noseworthy, Peter A, and Tison, Geoffrey H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Heart Disease, Prevention, Clinical Research, Cardiovascular, artificial intelligence, electrocardiogram, hypertrophic cardiomyopathy, machine learning, mavacamten
Abstract

BackgroundArtificial intelligence (AI) applied to 12-lead electrocardiographs (ECGs) can detect hypertrophic cardiomyopathy (HCM).ObjectivesThe purpose of this study was to determine if AI-enhanced ECG (AI-ECG) can track longitudinal therapeutic response and changes in cardiac structure, function, or hemodynamics in obstructive HCM during mavacamten treatment.MethodsWe applied 2 independently developed AI-ECG algorithms (University of California-San Francisco and Mayo Clinic) to serial ECGs (n = 216) from the phase 2 PIONEER-OLE trial of mavacamten for symptomatic obstructive HCM (n = 13 patients, mean age 57.8 years, 69.2% male). Control ECGs from 2,600 age- and sex-matched individuals without HCM were obtained. AI-ECG output was correlated longitudinally to echocardiographic and laboratory metrics of mavacamten treatment response.ResultsIn the validation cohorts, both algorithms exhibited similar performance for HCM diagnosis, and exhibited mean HCM score decreases during mavacamten treatment: patient-level score reduction ranged from approximately 0.80 to 0.45 for Mayo and 0.70 to 0.35 for USCF algorithms; 11 of 13 patients demonstrated absolute score reduction from start to end of follow-up for both algorithms. HCM scores were significantly associated with other HCM-relevant parameters, including left ventricular outflow tract gradient at rest, postexercise, and with Valsalva, and NT-proBNP level, independent of age and sex (all P < 0.01). For both algorithms, the strongest longitudinal correlation was between AI-ECG HCM score and left ventricular outflow tract gradient postexercise (slope estimate: University of California-San Francisco 0.70 [95% CI: 0.45-0.96], P < 0.0001; Mayo 0.40 [95% CI: 0.11-0.68], P = 0.007).ConclusionsAI-ECG analysis longitudinally correlated with changes in echocardiographic and laboratory markers during mavacamten treatment in obstructive HCM. These results provide early evidence for a potential paradigm for monitoring HCM therapeutic response.

Published
2023

6. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

Author

Maron, Martin S., Masri, Ahmad, Nassif, Michael E., Barriales-Villa, Roberto, Abraham, Theodore P., Arad, Michael, Cardim, Nuno, Choudhury, Lubna, Claggett, Brian, Coats, Caroline J., Düngen, Hans-Dirk, Garcia-Pavia, Pablo, Hagège, Albert A., Januzzi, James L., Kulac, Ian, Lee, Matthew M.Y., Lewis, Gregory D., Ma, Chang-Sheng, Michels, Michelle, Oreziak, Artur, Owens, Anjali T., Spertus, John A., Solomon, Scott D., Tfelt-Hansen, Jacob, van Sinttruije, Marion, Veselka, Josef, Watkins, Hugh C., Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Wohltman, Amy, and Olivotto, Iacopo

Published
2024
Full Text
View/download PDF

7. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy

Author

Masri, Ahmad, Cardoso, Rhanderson N., Abraham, Theodore P., Claggett, Brian L., Coats, Caroline J., Hegde, Sheila M., Kulac, Ian J., Lee, Matthew M.Y., Maron, Martin S., Merkely, Bela, Michels, Michelle, Olivotto, Iacopo, Oreziak, Artur, Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Solomon, Scott D., Wohltman, Amy, Kwong, Raymond Y., and Kramer, Christopher M.

Published
2024
Full Text
View/download PDF

8. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Author

Hegde, Sheila M., Claggett, Brian L., Wang, Xiaowen, Jering, Karola, Prasad, Narayana, Roshanali, Farideh, Masri, Ahmad, Nassif, Michael E., Barriales-Villa, Roberto, Abraham, Theodore P., Cardim, Nuno, Coats, Caroline J., Kramer, Christopher M., Maron, Martin S., Michels, Michelle, Olivotto, Iacopo, Saberi, Sara, Jacoby, Daniel L., Heitner, Stephen B., Kupfer, Stuart, Meng, Lisa, Wohltman, Amy, Malik, Fady I., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

9. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Author

MASRI, AHMAD, SHERRID, MARK V., ABRAHAM, THEODORE P., CHOUDHURY, LUBNA, GARCIA-PAVIA, PABLO, KRAMER, CHRISTOPHER M., BARRIALES-VILLA, ROBERTO, OWENS, ANJALI T., RADER, FLORIAN, NAGUEH, SHERIF F., OLIVOTTO, IACOPO, SABERI, SARA, TOWER-RADER, ALBREE, WONG, TIMOTHY C., COATS, CAROLINE J., WATKINS, HUGH, FIFER, MICHAEL A., SOLOMON, SCOTT D., HEITNER, STEPHEN B., JACOBY, DANIEL L., KUPFER, STUART, MALIK, FADY I., MENG, LISA, SOHN, REGINA L., WOHLTMAN, AMY, and MARON, MARTIN S.

Published
2024
Full Text
View/download PDF

11. Comprehensive Geriatric Assessment to Optimize the Management of Older Patients With Transthyretin Cardiac Amyloidosis

Author

Fumagalli, Carlo, Maurer, Mathew S., Fontana, Marianna, Fine, Nowell, Gillmore, Julian, Goyal, Parag, Nakagawa, Shunichi, Musumeci, Beatrice, Grogan, Martha, Marfella, Raffaele, Limongelli, Giuseppe, Bo, Mario, Longhi, Simone, Cuddy, Sarah, Masri, Ahmad, Olivotto, Iacopo, Perfetto, Federico, Ungar, Andrea, Marchionni, Niccolò, and Cappelli, Francesco

Published
2024
Full Text
View/download PDF

17. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Author

Maron, Martin S., Mahmod, Masliza, Abd Samat, Azlan Helmy, Choudhury, Lubna, Massera, Daniele, Phelan, Dermot M.J., Cresci, Sharon, Martinez, Matthew W., Masri, Ahmad, Abraham, Theodore P., Adler, Eric, Wever-Pinzon, Omar, Nagueh, Sherif F., Lewis, Gregory D., Chamberlin, Paul, Patel, Jai, Yavari, Arash, Dehbi, Hakim-Moulay, Sarwar, Rizwan, Raman, Betty, Valkovič, Ladislav, Neubauer, Stefan, Udelson, James E., and Watkins, Hugh

Published
2024
Full Text
View/download PDF

19. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis

Author

Ioannou, Adam, Cappelli, Francesco, Emdin, Michele, Nitsche, Christian, Longhi, Simone, Masri, Ahmad, Cipriani, Alberto, Zampieri, Mattia, Colio, Federica, Poledniczek, Michael, Porcari, Aldostefano, Razvi, Yousuf, Aimo, Alberto, Vergaro, Giuseppe, De Michieli, Laura, Rauf, Muhammad U., Patel, Rishi K., Villanueva, Eugenia, Lustig, Yael, Venneri, Lucia, Martinez-Naharro, Ana, Lachmann, Helen, Wechalekar, Ashutosh, Whelan, Carol, Petrie, Aviva, Hawkins, Philip N., Solomon, Scott, Gillmore, Julian D., and Fontana, Marianna

Published
2024
Full Text
View/download PDF

23. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design

Author

Coats, Caroline J., Maron, Martin S., Abraham, Theodore P., Olivotto, Iacopo, Lee, Matthew M.Y., Arad, Michael, Cardim, Nuno, Ma, Chang-Sheng, Choudhury, Lubna, Düngen, Hans-Dirk, Garcia-Pavia, Pablo, Hagège, Albert A., Lewis, Gregory D., Michels, Michelle, Oreziak, Artur, Owens, Anjali T., Tfelt-Hansen, Jacob, Veselka, Josef, Watkins, Hugh C., Heitner, Stephen B., Jacoby, Daniel L., Kupfer, Stuart, Malik, Fady I., Meng, Lisa, Wohltman, Amy, and Masri, Ahmad

Published
2024
Full Text
View/download PDF

34. Are pediatric preformed zirconia crowns comparable to preformed metal crowns? A real-life retrospective study.

Author

Shedeed, Omar M., Al Masri, Ahmad, Splieth, Christian H., Pink, Christiane, and Santamaria, Ruth M.

Subjects
ANALYSIS of heavy metals, DENTAL crowns, DENTAL implants, PULPOTOMY, RETROSPECTIVE studies, MATHEMATICAL variables, T-test (Statistics), COMPARATIVE studies, DESCRIPTIVE statistics, CHI-squared test, KAPLAN-Meier estimator, ENDODONTICS, DENTAL caries in children
Abstract

Objectives: Although minimally and noninvasive caries management are advocated in pediatric dentistry, extensive caries progression often requires endodontic treatment followed by crowning of the tooth. Thus, the aim of this study was to evaluate the success of esthetic preformed zirconia crowns (PZCs) compared to the standard preformed metal crowns (PMCs) after pulpotomy in primary molars retrospectively. Method and materials: Patients' digital records in a specialized pediatric clinic in Germany were analyzed to include 2- to 9-year-olds, who had received one or more PMCs or PZCs after a pulpotomy between 2016 and 2020. The main outcomes were success, minorfailure (restoration loss, wear, or fracture), or major failure (need for extraction or pulpectomy). Results: In total, 151 patients with 249 teeth (PMC, n = 149; PZC, n = 100) were included. The mean follow-up time was (19.9 months), with 90.4% of the crowns fol-lowed for at least 18 months. The majority of the crowns were considered successful (94.4%). The differences in the success rates between PMCs (96%) and PZCs (92%) did not reach the level of statistical significance (P = .182). All minor failures (1.6%) were in the PZC group and located in the maxilla. Independent of crown type, especially first primary molars were prone to failure (7.9%; second primary molars, 3.3%). Conclusion: PMCs and PZCs both show high clinical success rates as restorations of primary teeth after a pulpotomy. However, there was a tendency of greater minor or major failure in the PZC group. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM.

Author

Masri, Ahmad, Choudhury, Lubna, Barriales-Villa, Roberto, Elliott, Perry, Maron, Martin S., Nassif, Michael E., Oreziak, Artur, Owens, Anjali Tiku, Saberi, Sara, Tower-Rader, Albree, Rader, Florian, Garcia-Pavia, Pablo, Olivotto, Iacopo, Nagueh, Sherif F., Wang, Andrew, Heitner, Stephen B., Jacoby, Daniel L., Kupfer, Stuart, Malik, Fady I., and Melloni, Chiara

Subjects
*HYPERTROPHIC cardiomyopathy, *TERMINATION of treatment, *CLINICAL trials, *TROPONIN I, *PEPTIDES
Abstract

Standard-of-care (SoC) medications for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) are recommended as first-line therapy despite the lack of evidence from controlled clinical trials and well known off-target side effects. We describe the impact of SoC therapy downtitration and withdrawal in patients already receiving aficamten in FOREST-HCM (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy; NCT04848506). Patients receiving SoC therapy (beta-blocker, nondihydropyridine calcium-channel blocker, and/or disopyramide) were eligible for protocol-guided SoC downtitration and withdrawal at the discretion of the investigator and after achieving a stable dose of aficamten for ≥4 weeks. Successful SoC withdrawal was defined as at least a 50% dose-reduction in ≥1 medication. Adverse events (AEs) were prospectively evaluated 1 to 2 weeks after any SoC withdrawal. Of 145 patients with oHCM who were followed for at least 24 weeks (mean age 60.5 ± 13.2 years; 44.8% female; 42% NYHA functional class III), 136 (93.8%) were receiving ≥1 SoC therapy; of those, 64 (47%) had an attempt at withdrawal, with 59 (92.2%) successful. Thirty-eight (64.4%) patients completely discontinued ≥1 medication, and 27 (45.8%) achieved aficamten monotherapy with 2 later restarting a SoC medication. There were no significant differences in baseline characteristics on day 1 in FOREST-HCM in those with a SoC-withdrawal vs no-withdrawal attempt. In patients who underwent successful SoC therapy withdrawal, NYHA functional class improved by ≥1 class in 79.2% from baseline, Kansas City Cardiomyopathy Questionnaire–Clinical Summary Score improved to 83.0 ± 15.8 points, and resting and Valsalva left ventricular outflow tract gradient improved to 14.3 ± 10.9 and 32.9 ± 21.4 mm Hg, respectively. N-terminal pro–B-type natriuretic peptide levels improved to a median of 220.0 pg/mL (Q1-Q3: 102.0-554.0.0 pg/mL) and high-sensitivity troponin I improved to a median of 6.0 ng/L (Q1-Q3:3.5-10.7 ng/L). Downtitration and withdrawal of SoC therapy did not impact these results (all P values for change were >0.05), and these changes were similar in patients who did not undergo SoC therapy withdrawal. There were no serious AEs attributed to SoC withdrawal and treatment emergent AEs were similar between groups. In FOREST-HCM, one-half of the patients with oHCM attempted downtitration and withdrawal of SoC medications while receiving aficamten treatment, with infrequent instances of resumption of SoC. Stopping and dose reduction of SoC medications were well tolerated with no adverse consequences in clinical measures of efficacy (Follow-Up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in Hypertrophic Cardiomyopathy [FOREST-HCM]; NCT04848506) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Author

Maron, Martin S., primary, Masri, Ahmad, additional, Nassif, Michael E., additional, Barriales-Villa, Roberto, additional, Arad, Michael, additional, Cardim, Nuno, additional, Choudhury, Lubna, additional, Claggett, Brian, additional, Coats, Caroline J., additional, Düngen, Hans-Dirk, additional, Garcia-Pavia, Pablo, additional, Hagège, Albert A., additional, Januzzi, James L., additional, Lee, Matthew M.Y., additional, Lewis, Gregory D., additional, Ma, Chang-Sheng, additional, Michels, Michelle, additional, Olivotto, Iacopo, additional, Oreziak, Artur, additional, Owens, Anjali T., additional, Spertus, John A., additional, Solomon, Scott D., additional, Tfelt-Hansen, Jacob, additional, van Sinttruije, Marion, additional, Veselka, Josef, additional, Watkins, Hugh, additional, Jacoby, Daniel L., additional, Heitner, Stephen B., additional, Kupfer, Stuart, additional, Malik, Fady I., additional, Meng, Lisa, additional, Wohltman, Amy, additional, and Abraham, Theodore P., additional

Published
2024
Full Text
View/download PDF

44. Evolution of Transthyretin Amyloid Cardiomyopathy Characteristics Over a 20 Year Period: A Multicenter Study of 1,168 Patients

Author

Masri, Ahmad, primary, Bhattacharya, Priyanka, primary, Medoff, Brent, primary, U., Ain, primary, Chandrashekar, Pranav, primary, Ives, Lauren, primary, Mirabal, Alfonsina, primary, Teruya, Sergio, primary, Zhao, Yuanzi, primary, Huang, Shuaiqi, primary, Wu, Yanjun, primary, Wang, Xiaofeng, primary, W., Brett, primary, Maurer, Mat, primary, Hanna, Mazen, primary, and Soman, Prem, primary

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results